Heart, Lung and Circulation
Volume 16, Issue 2 , Pages 70-78 , April 2007

Delayed Contrast Enhancement Magnetic Resonance Imaging for the Assessment of Cardiac Disease

  • Constantin B. Marcu, MD

      Affiliations

    • Hospital of Saint Raphael—Yale University, New Haven, CT, USA
    • Corresponding Author InformationCorresponding author at: Cardiac Diagnostic Unit, Room PG 10, Hospital of Saint Raphael, 1450 Chapel St., New Haven, CT 06511, USA. Tel.: +1 203 789 3135; fax: +1 203 789 6046.
    • ,
  • Robin Nijveldt, MD

      Affiliations

    • VU University Medical Center, Amsterdam, The Netherlands
    • Dr Nijveldt is supported by the grant number 2003B126 from the Netherlands Heart Foundation.
    • ,
  • Aernout M. Beek, MD

      Affiliations

    • VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Albert C. Van Rossum, MD, PhD

      Affiliations

    • VU University Medical Center, Amsterdam, The Netherlands

Received 8 July 2006 ,Revised 15 August 2006 ,Accepted 22 September 2006.

References 

  1. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215–223
  2. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J. 2004;25:1940–1965
  3. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol. 1984;142:619–624
  4. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation. 1995;92:1117–1125
  5. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson. 2003;5:505–514
  6. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–1453
  7. Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging. 2004;19:771–788
  8. Heart disease and stroke statistics—2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006;113:85–151.
  9. Taylor GJ, Humphries J, Mellits ED, Pitt B, Schulze RA, Griffith LS, et al. Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation. 1980;62:960–970
  10. Mock MB, Ringqvist I, Fisher LD, Davis KB, Chaitman BR, Kouchoukos NT, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation. 1982;66:562–568
  11. Sheehan FH. Determinants of improved left ventricular function after thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol. 1987;9:937–944
  12. Lewis SJ, Sawada SG, Ryan T, Segar DS, Armstrong WF, Feigenbaum H. Segmental wall motion abnormalities in the absence of clinically documented myocardial infarction: clinical significance and evidence of hibernating myocardium. Am Heart J. 1991;121:1088–1094
  13. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978–985
  14. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211–221
  15. Gropler RJ, Bergman SR. Myocardial viability—what is the definition?. J Nucl Med. 1991;32:10–12
  16. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527–533
  17. Eitzman D, al-Aouar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559–565
  18. Marwick TH, Nemec JJ, Lafont A, Salcedo EE, MacIntyre WJ. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol. 1992;69:854–859
  19. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–1158
  20. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–3326
  21. McNamara MT, Tscholakoff D, Revel D, Soulen R, Schechtmann N, Botvinick E, et al. Differentiation of reversible and irreversible myocardial injury by MR imaging with and without gadolinium-DTPA. Radiology. 1986;158:765–769
  22. Judd RM, Lugo-Olivieri CH, Arai M, Kondo T, Croisille P, Lima JA, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. 1995;92:1902–1910
  23. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeight ER, Furuta T, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation. 1998;98:1006–1014
  24. Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann H, Higgins CB. Magnetic resonance characterization of the peri-infarct zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation. 2001;103:871–876
  25. Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol. 2004;43:2253–2599
  26. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–772
  27. Underwood SR, Bax JJ, vom Dahl J, Henein MY, Knuuti J, van Rossum AC, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J. 2004;25:815–836
  28. Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JA. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation. 2002;106:1083–1089
  29. Beek AM, Kuhl HP, Bondarenko O, Twisk JW, Hofman MB, van Dockum WG, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol. 2003;42:895–901
  30. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110:1535–1541
  31. Kim RJ, Shah DJ. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is “alive” is not enough. Heart. 2004;90:137–140
  32. Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, et al. Gadolinium Cardiovascular Magnetic Resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing ß-blocker therapy. Circulation. 2003;108:1945–1953
  33. Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Ravul U, Webster J, et al. Effects of carvedilol on left ventricular remodeling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart. 2004;90:760–764
  34. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000;2:271–278
  35. Ramani K, Judd RM, Holly TA, Parrish TB, Rigolin VH, Parker MA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation. 1998;98:2687–2694
  36. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374–379
  37. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging. Comparison with positron emission tomography. Circulation. 2002;105:162–167
  38. Kuhl HP, Beek AM, van der Weerdt AP, Hofman MB, Visser CA, Lammertsma AA, et al. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2003;41:1341–1348
  39. Knuesel PR, Nanz D, Wyss C, Buechi M, Kaufmann PA, von Schulthess GK, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation. 2003;108:1095–1100
  40. Kuhl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J. 2006;27(7):846–853
  41. Srichai MB, Junor C, Rodriguez LL, Stillman AE, Grimm RA, Lieber ML, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J. 2006;152:75–84
  42. Richardson P, McKenna W, Bristow M. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842
  43. Bender JR. Idiopathic dilated cardiomyopathy. An immunologic, genetic or infectious disease, or all of the above?. Circulation. 1991;83:704–706
  44. Wu E, Judd RM, Vargas J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001;357:21–28
  45. McCrohon JA, Moon JC, Prasad SK. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–59
  46. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60:1340–1355
  47. Assomul RG, Prasad SK, Burmna E. Cardiovascular magnetic resonance, fibrosis and prognosis in dilated cardiomyopathy. J Cardiovasc Magn Reson. 2006;8:3–4[abstract]
  48. Wynne J, Braunwald E. Hypertrophic Cardiomyopathy. In:  Zipes DP,  Libby P,  Bonow RO,  Braunwald E editor. Braunwald's Heart Disease: a textbook of cardiovascular medicine. Philadelphia, Pennsylvania: Elsevier Saunders; 2005;p. 1667–1682
  49. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156–2164
  50. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–1567
  51. van Dockum WG, Ten Cate FJ, Ten Berg JM, Beek AM, Twisk JW, Vos J, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol. 2004;43:27–34
  52. van Dockum WG, Beek AM, Ten Cate FJ, Ten Berg JM, Bondarenko O, Gotte MJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005;111:2503–2508
  53. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson–Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24:2151–2155
  54. Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2001;38:1773–1781
  55. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98–103
  56. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994;71:215–218
  57. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3–14
  58. Friedrich MG, Strohm O, Schulz-Menger J. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998;97:1802–1809
  59. Mahrholdt H, Goedecke C, Wagner A. Cardiovascular magnetic resonance assessment of human myocarditis; a comparison to histology and molecular pathology. Circulation. 2004;109:1250–1258
  60. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–1211
  61. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461–1474
  62. Abeler V. Sarcoidosis of the cardiac conducting system. Am Heart J. 1979;97:701–707
  63. Sharma OP. Cardiac and neurologic dysfunction in sarcoidosis. Clin Chest Med. 1997;18:813–825
  64. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med. 2001;110:520–527
  65. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895–1901
  66. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010
  67. Wynne J, Braunwald E. Restrictive and infiltrative cardiomyopathies. In:  Zipes DP,  Libby P,  Bonow RO,  Braunwald E editor. Braunwald's heart disease: a textbook of cardiovascular medicine. Philadelphia, Pennsylvania: Elsevier Saunders; 2005;p. 1682–1692
  68. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–193
  69. Bogaert J, Taylor AM. Nonischemic myocardial disease. In:  Bogart J,  Dymarkowski S,  Taylor AM editor. Clinical cardiac MRI. Berlin, Germany: Springer; 2005;p. 217–271
  70. Rochitte CE, Oliveria PF, Andrade JM, Ianni BM, Parga JR, Avila LF, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol. 2005;46:1553–1558
  71. Katz J, Whang J, Boxt LM, Barst RJ. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. J Am Coll Cardiol. 1993;21:1475–1481
  72. Boxt LM, Katz J, Kolb T, Czegledy FP, Barst RJ. Direct quantitation of right and left ventricular volumes with nuclear magnetic resonance imaging in patients with primary pulmonary hypertension. J Am Coll Cardiol. 1992;19:1508–1515
  73. Kroft LJM, Simons P, van Laar JM, de Roos A. Patients with pulmonary fibrosis: cardiac function assessed with MR imaging. Radiology. 2000;216:464–471
  74. Blyth KG, Groenning BA, Martin TN, Foster JA, Mark PB, Dargie HJ, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26(19):1993–1999

PII: S1443-9506(06)00224-1

doi: 10.1016/j.hlc.2006.09.006

Heart, Lung and Circulation
Volume 16, Issue 2 , Pages 70-78 , April 2007

Article Tools

* Image Usage & Resolution